Mogynin (sildenafil) coated tablets 100 mg. №4


Mogynin is used in men for erectile dysfunction (inability to achieve or maintain an erection of the penis, ensuring successful intercourse).



Mogynin composition and form of release
Active ingredients: sildenafil (100 mg).
Available in tablet form.

Pharmacological properties
It is a remedy used for erectile disorders. Restores decreased erectile function by increasing blood flow to the penis. The mechanism of action is based on the release of nitric oxide in the corpora cavernosa at the time of sexual arousal. Free nitric oxide activates the enzyme guanylate cyclase, stimulating an increase in cGMP levels, which causes relaxation of the smooth muscle fibers of the corpora cavernosa and an increase in blood flow.

Mogynin is used in men for erectile dysfunction (inability to achieve or maintain an erection of the penis, ensuring successful intercourse).


  • if you are allergic to sildenafil;
  • with intolerance to auxiliary components;
  • with the simultaneous use of drugs-donors of nitric oxide (for example, amyl nitrite) or nitrates;
  • in conditions where sexual activity is not recommended (severe heart failure, unstable angina pectoris);
  • with loss of vision in one eye due to non-arterial anterior ischemic neuropathy of the optic nerve;
  • in case of severe liver dysfunction;
  • with arterial hypotension (blood pressure below 90/50 mm Hg);
  • with recent stroke, myocardial infarction;
  • with hereditary degenerative changes in the retina (for example, retinitis pigmentosa).

Does not apply to children.

Application during pregnancy and lactation
Mogynin is not intended for use in women.

Method of administration and dosage
Mogynin is used internally.
Sexual arousal is required for this drug to work effectively.
The tablet is taken one hour before sexual activity.
The standard single dose is 50 mg (preferably on an empty stomach). The maximum single dose is 100 mg.

Possible symptoms: blurred vision, headache, flushing, dyspepsia, dizziness, nasal congestion.
In case of overdose, resort to standard supportive measures.

Side effects:

  • Neurological disorders: headache, flushing, migraine, ataxia, tremor, weakened reflexes, neuralgia, paresthesia, hypoesthesia, depression, fainting, insomnia / drowsiness, dizziness.
  • Ophthalmic disorders: visual impairment (hypersensitivity to light, changes in color perception, blurred vision), conjunctivitis, mydriasis, cataracts, hemorrhages in the eyeball, pain in the eyeballs, xerophthalmia.
  • Otolaryngological disorders: deafness, ringing in the ears.
  • Respiratory disorders: nasal congestion, pharyngitis, bronchitis, sinusitis, laryngitis, dyspnea, increased cough, increased phlegm, bronchial asthma.
  • Cardiovascular disorders: arterial hypotension, tachycardia, orthostatic hypotension, palpitations, angina pectoris, myocardial ischemia, cardiomyopathy, ECG changes, heart failure, AV block, cerebral vascular thrombosis, cardiac arrest.
  • Hematological disorders: anemia, leukopenia.
  • Gastrointestinal disorders: glossitis, stomatitis, gingivitis, dry mouth, nausea, dysphagia, esophagitis, gastritis, colitis, gastroenteritis, rectal bleeding.
  • Metabolic disorders: thirst, hyperuricemia, hypernatremia, gout, labile diabetes, hyper- / hypoglycemia.
  • Genitourinary disorders: urinary tract infections, nocturia, cystitis, frequent urination, urinary incontinence, anorgasmia, ejaculation disorders, gynecomastia, edema of the genitals.
  • Musculoskeletal disorders: ossalgia, arthritis, myalgia, arthrosis, tendon rupture, myasthenia gravis, synovitis, tendosynovitis.
  • Dermatological disorders: contact dermatitis, rash, urticaria, pruritus, herpes simplex, skin ulceration, exfoliative dermatitis, photosensitivity.
  • Others: peripheral edema, pain syndromes, sweating, chills, shock, allergic reactions.

Storage conditions and periods
Store Mogynin for no more than two years at temperatures up to +25 ° C.
It is forbidden to use after the expiry date indicated on the package.
Parents are obliged to ensure the safety of children, excluding the possibility of their access to medicine.